<?xml version="1.0" encoding="UTF-8"?>
<p>TB patients with COVID-19 may require an adapted therapeutic approach compared with patients without COVID-19. Switching to intravenous anti-TB drugs is recommended for patients in intensive care in order to optimise drug exposure in critically ill patients [
 <xref rid="C163" ref-type="bibr">163</xref>]. Therapeutic solutions for COVID-19 in TB patients need to be considered in the perspective of anti-TB treatment. However, more evidence ideally from clinical trials is necessary.
</p>
